Stockreport

Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive [Yahoo! Finance]

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF growth), turned cash-flow positive in the quarter, and raised 2026 product revenue guidance to $480–$495 million while continuing to invest in commercialization and pipe [Read more]